Patents Assigned to Janssen Pharmaceuticals, Inc.
  • Publication number: 20210300868
    Abstract: The present invention concerns substituted indoline derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Application
    Filed: May 28, 2021
    Publication date: September 30, 2021
    Applicants: Janssen Pharmaceuticals, Inc., Katholieke Universiteit Leuven
    Inventors: Jean-François Bonfanti, Bart Rudolf Romanie Kesteleyn, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand, Erwin Coesemans, Benoît Christian Albert Ghislain De Boeck, Pierre Jean-Marie Bernard Raboisson
  • Publication number: 20210290855
    Abstract: A grip accessory for a manual injection device comprises a housing having a generally hollow body for supporting a manual injection device therein. The housing comprises a distal portion comprising a first opening into which a manual injection device can be inserted, a proximal portion comprising a second opening through which a needle of the manual injection device is extendable, the proximal portion comprising a skin contacting surface at a proximal end of the device. An intermediate portion extends between the proximal and distal portions and guide means is provided on an interior surface of the distal portion for guiding a plunger rod of an injection device during delivery of an injection.
    Type: Application
    Filed: May 29, 2018
    Publication date: September 23, 2021
    Applicant: Janssen Pharmaceuticals, Inc.
    Inventors: James McLUSKY, Nick FOLEY, Jimmy MOWER, Ian SCRIMGEOUR, Michael CANNAMELA, Peter KRULEVITCH, Kui LIU
  • Patent number: 11124552
    Abstract: Liposomes containing tau peptides, preferably phosphorylated tau peptides, and conjugates containing tau peptides, preferably phosphorylated tau peptides, conjugated to an immunogenic carrier are described. Pharmaceutical compositions and uses of the liposomes and/or conjugates for treating or preventing a neurodegenerative disease or disorder, such as Alzheimer's Disease, are also described.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: September 21, 2021
    Assignees: AC Immune SA, Janssen Pharmaceuticals, Inc.
    Inventors: Elizabeth Anne Ramsburg, Donata De Marco, Charlotte Sadaka, Jaap Goudsmit, Andreas Muhs, Maria Pihlgren Bosch, Marija Vukicevic Verhille, Nicolas Piot, Saroj Raj Ghimire
  • Patent number: 11083786
    Abstract: The present disclosure generally relates to the use of different self-amplifying RNA molecules to enhance immune responses, for example immune responses following prophylactic vaccination or therapeutic administration. Some embodiments relate to compositions and methods for inducing an immune response in a subject using prime-boost immunization regimens.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: August 10, 2021
    Assignee: JANSSEN PHARMACEUTICALS, INC.
    Inventors: Kurt Iver Kamrud, Nathaniel Stephen Wang, Parinaz Aliahmad, Jason DeHart
  • Patent number: 11083707
    Abstract: The present invention relates to substituted indoline derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: August 10, 2021
    Assignees: Janssen Pharmaceuticals, Inc., Katholieke Universiteit Leuven
    Inventors: Bart Rudolf Romanie Kesteleyn, Jean-François Bonfanti, Erwin Coesemans, Pierre Jean-Marie Bernard Raboisson, Arnaud Didier M Marchand, Dorothée Alice Marie-Eve Bardiot
  • Patent number: 11071729
    Abstract: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: July 27, 2021
    Assignees: Addex Pharmaceuticals S.A., Janssen Pharmaceuticals, Inc.
    Inventors: Jose Maria Cid-Nunez, Andres Avelino Trabanco-Suarez, Gregor James MacDonald, Guillaume Albert Jacques Duvey, Terry Patrick Finn
  • Patent number: 11053196
    Abstract: The present invention concerns substituted indoline derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: July 6, 2021
    Assignees: Janssen Pharmaceuticals, Inc., Kathalieke Universiteif Leuven
    Inventors: Jean-François Bonfanti, Bart Rudolf Romanie Kesteleyn, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand, Erwin Coesemans, Benoît Christian Albert Ghislain De Boeck, Pierre Jean-Marie Bernard Raboisson
  • Patent number: 11033633
    Abstract: Compositions and methods for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) are described. In particular, multivalent vaccines containing O-antigen polysaccharide covalently bound to an exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein that can withstand multiple environmental stresses are described.
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: June 15, 2021
    Assignee: JANSSEN PHARMACEUTICALS, INC.
    Inventors: Olga Labovitiadi, Wouter Frank Tonnis, Francesco Doro, Janik Adriaansen
  • Publication number: 20210171462
    Abstract: The present invention relates to mono- or di-substituted indole compounds, methods to prevent or treat dengue viral infections by using the compounds and also relates to use of the compounds as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Application
    Filed: December 31, 2020
    Publication date: June 10, 2021
    Applicants: Janssen Pharmaceuticals, Inc., Katholieke Universiteit Leuven
    Inventors: Bart Rudolf Romanie Kesteleyn, Jean-François Bonfanti, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand
  • Patent number: 10919854
    Abstract: The present invention relates to mono- or di-substituted indole compounds, methods to prevent or treat dengue viral infections by using the compounds and also relates to use of the compounds as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: February 16, 2021
    Assignees: Janssen Pharmaceuticals, Inc., Katholieke Universiteit Leuven
    Inventors: Bart Rudolf Romanie Kesteleyn, Jean-François Bonfanti, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand
  • Patent number: 10913716
    Abstract: The present invention concerns substituted indoline compounds, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: February 9, 2021
    Assignees: Janssen Pharmaceuticals, Inc., Katholieke Universiteit Leuven
    Inventors: Bart Rudolf Romanie Kesteleyn, Pierre Jean-Marie Bernard Raboisson, Jean-François Bonfanti, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand
  • Patent number: 10864263
    Abstract: Provided are methods for generating an immune response against a Zika virus in a human subject in need thereof. The methods comprise administering to the subject a pharmaceutical composition comprising adenoviral vectors encoding a Zika virus antigen and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: December 15, 2020
    Assignees: Janssen Pharmaceuticals, Inc., Beth Israel Deaconess Medical Center. Inc.
    Inventors: Dan Barouch, Macaya Julie Douoguih, Gaston Rafael Picchio
  • Publication number: 20200330499
    Abstract: Described are RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B Virus (HBV) used in combination with a capsid assembly modulator (CAM) and methods of administering same. The HBV RNAi agents and CAMs are administered in ratios to effectively inhibit HBV gene expression and to treat diseases and conditions associated with HBV infection.
    Type: Application
    Filed: April 17, 2020
    Publication date: October 22, 2020
    Applicant: Janssen Pharmaceuticals, Inc.
    Inventors: Michael BIERMER, Ronald KALMEIJER, Oliver LENZ, Maria Gloria BEUMONT-MAUVIEL, Jan SNOEYS, Kenneth Alan SIMMEN
  • Publication number: 20200332297
    Abstract: Described are RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B Virus (HBV) used in combination with a capsid assembly modulator (CAM) and methods of administering same. The HBV RNAi agents and CAMs are administered in ratios to effectively inhibit HBV gene expression and to treat diseases and conditions associated with HBV infection.
    Type: Application
    Filed: April 17, 2020
    Publication date: October 22, 2020
    Applicant: Janssen Pharmaceuticals, Inc.
    Inventors: Michael BIERMER, Ronald KALMEIJER, Oliver LENZ, Maria Gloria BEUMONT-MAUVIEL, Jan SNOEYS, Kenneth Alan SIMMEN
  • Patent number: 10786484
    Abstract: The present invention concerns mono- or di-substituted indole compounds, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: September 29, 2020
    Assignees: Janssen Pharmaceuticals, Inc., Katholieke Universiteit Leuven
    Inventors: Bart Rudolf Romanie Kesteleyn, Jean-François Bonfanti, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand
  • Publication number: 20200299235
    Abstract: The present invention concerns substituted indoline derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Application
    Filed: June 5, 2020
    Publication date: September 24, 2020
    Applicants: Janssen Pharmaceuticals, Inc., Katholieke Universiteit Leuven
    Inventors: Bart Rudolf Romanie Kesteleyn, Pierre Jean-Marie Bernard Raboisson, Jean-François Bonfanti, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand
  • Patent number: D902391
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: November 17, 2020
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Ian Scrimgeour, James McLusky, Nick Foley, Peter Krulevitch, Jimmy Mower, Michael Cannamela, Kui Liu
  • Patent number: D902392
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: November 17, 2020
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Ian Scrimgeour, James McLusky, Nick Foley, Peter Krulevitch, Jimmy Mower, Michael Cannamela, Kui Liu
  • Patent number: D902393
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: November 17, 2020
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Michael Cannamela, Rochelle Kleinberg, Peter Krulevitch
  • Patent number: D903108
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: November 24, 2020
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Ian Scrimgeour, James McLusky, Nick Foley, Peter Krulevitch, Jimmy Mower, Michael Cannamela, Kui Liu